(Nasdaq: NBIX), a biopharmaceutical company focused on neurological and
endocrine diseases and disorders, announced today that Gary Lyons, President
and CEO, will present at the 12th Annual NewsMakers in the Biotech Industry
Conference at the Sheraton New York Hotel + Towers on Friday, September 9,
2005. Pacific Daylight Time (PDT) and will include marketing
highlights for indiplon as well as an update on the Company's broad
development pipeline and research programs.neurocrine.
A replay of the webcast will be available approximately one hour after the
presentation concludes and will be archived until Friday, September 23, 2005.

For more information about clinical trial sites and specific study
protocol, please call 1-800-624-7994.

infectious neurological

The presentation will be webcast
and can be accessed on the Company's website at http://www.
If you are unable to attend the webcast and would like further information
on this announcement please contact the Investor Relations Department at
Neurocrine Biosciences at (858) 617-7600 and ask for Claudia Woodworth or
Elizabeth Foster.

Neurocrine Biosciences, Inc.

PRESS RELEASE Centocor Extends Patient Enrollment to Evaluate CNTO 1275 in Treatment of Active Crohn's Disease

Subjects will be permitted to remain on certain standard CD
medications, including steroids and immunomodulators, while participating
in the study.
Centocor is a wholly owned subsidiary of Johnson & Johnson, the worldwide
manufacturer of healthcare products.

syndrome isaacs

Company Presentation and Webcast on Friday, September 9, 2005

SAN DIEGO, Neurocrine Biosciences, Inc.
Centocor, Inc. announced today the
extension of patient enrollment for a Phase II trial to evaluate the safety
and efficacy of CNTO 1275 for reducing the signs and symptoms of active
Crohn's disease (CD), a serious gastrointestinal disorder.

syndrome isaacs

The live presentation will take place at 2:50 p. CNTO 1275 is a
human monoclonal antibody that targets interleukin 12 (IL-12) and
interleukin 23 (IL-23), proteins that occur naturally in the immune system
and are believed to play a role in the inflammation associated with CD.

squander fever

Neurocrine Biosciences , Inc.

"This study will evaluate the effect of a targeted, human anti-IL-12
monoclonal antibody on Crohn's disease and its symptoms," said Dennis S.I.

conditions fever

Eastern Daylight Time
(EDT) / 11:50 a.m. Our product
candidates address some of the largest pharmaceutical markets in the world
including insomnia, anxiety, depression, diabetes, multiple sclerosis,
irritable bowel syndrome, eating disorders , pain, and autoimmunity.

About Crohn's Disease

CD is a chronic inflammatory bowel disorder that commonly affects the lower
part of the small intestine and the large intestine and typically begins in
late childhood or early adulthood.

diseases squander

Neurocrine Biosciences to Present at the BioCentury Annual NewsMakers in the Biotech Industry Conference

com. news releases are available through the Company 's
website via the Internet at http://www.

Contact: Claudia Woodworth or Elizabeth Foster at 858-617-7600. Patients will be monitored through 28 weeks with an
additional visit at week 54 for a final blood test. The disease causes inflammation of the
gastrointestinal tract, typically resulting in symptoms such as diarrhea,
fever, abdominal pain and weight loss. It is estimated that 500,000
Americans and more than 400,000 people in Europe and Canada suffer from
this gastrointestinal disorder.

About Centocor

Centocor is a leading biopharmaceutical company that creates , acquires and
markets cost-effective therapies that yield long-term benefits for patients
and the healthcare community.

muscle squander

is a product-based biopharmaceutical company
focused on neurological and endocrine diseases and disorders.com. "We look forward to further analysis and evaluation of this
therapy as a potential treatment for patients with moderate to severe
Crohn's disease."

Patients who are eligible to participate in the 28-week study will be
randomized at week 0 to one of four treatment groups to receive active drug
or placebo.), such as arthritis and
inflammatory skin diseases.

Centocor's products, developed primarily
through monoclonal antibody technology, help physicians deliver innovative
treatments to improve human health and restore patients' quality of life.

squander neurological

neurocrine.

fever syndrome

diseases isaacs

Riff, MD, Medical Director, Advanced Clinical Research Institute, Anaheim,
California .

squander health

m.M.D.

infectious muscle

Viewers are encouraged to visit the website approximately 5 minutes prior to
the presentation to download or install any necessary software. The company is dedicated to the research and
development of treatments for a wide range of diseases including cancer,
infectious diseases, cardiovascular and metabolic diseases and
Immune-Mediated Inflammatory Disorders (I.

rickettsial conditions

---

- - kjjkjk

Loading...

(Note: These pages use the Atlas Content Safeguard System (ACSS) and require that Javascript is enabled for viewing.)